Inicio › Cáncer de seno › Illinois
Ensayos clínicos de Cáncer de seno en Illinois
81 estudios sobre Cáncer de seno buscan participantes en Illinois.
Ciudades en Illinois
- Chicago58 estudios
- Evanston13 estudios
- Waukegan12 estudios
- Cicero11 estudios
- Champaign11 estudios
- Naperville9 estudios
- Peoria8 estudios
- Decatur8 estudios
- Springfield8 estudios
- Aurora7 estudios
- Arlington Heights7 estudios
- Carbondale6 estudios
- Bloomington5 estudios
- North Peoria5 estudios
- Rockford5 estudios
- Danville5 estudios
- Charleston5 estudios
- Galesburg5 estudios
- Joliet4 estudios
- Elgin4 estudios
Texto oficial del estudio (inglés)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Orchard Healthcare Research Inc.- Skokie, Skokie
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06324357PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT05868226Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Northwestern Medicine Chicago Proton Center, Warrenville
ReclutandoFase 2
Edades de 50 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT01766297Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Affiliated Oncologists IL, Chicago
- Hope And Healing Care, Hinsdale
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 29 sept 2026 · NCT05827081Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07553234A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- City of Hope Chicago, Zion
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07007559A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Rush University Medical Center ( Site 0079), Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06312176A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06172478Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Peoria
- Clinical Trial Site, Urbana
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwestern University, Chicago
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07174336Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Chicago, Chicago
ReclutandoSe aceptan voluntarios sanos
Edades de 30 a 74 · Mujeres · Actualizado el 21 sept 2026 · NCT02620852A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07109726ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Cancer Care Specialists, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
- Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07173751A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Illinois Cancer Specialists, Arlington Heights
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06492616SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Orchard Healthcare Research Inc., Skokie
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT05935384Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT03424005Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Orchard Healthcare Research Inc. ( Site 0006), Skokie
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06797635Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Carle Cancer Center, Urbana
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT05386108A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- NorthShore University Health System - Evanston Hospital, Evanston
- NorthShore University HealthSystem - Evanston Hospital, Evanston
- Duly Health and Care, Lisle
- y 2 más
ReclutandoFase 1
Edades de 18 a 55 · Mujeres · Actualizado el 9 sept 2026 · NCT07310420A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Chicago, Chicago
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT07100106A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Evanston
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07647328Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Northwestern University, Chicago
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT05315700Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06062498Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Southern Illinois Hospital Services, Carbondale
- Cancer Care Specialist of Illinois, O'Fallon
ReclutandoEstudio observacional
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Cancer Care Specialists of Central Illinois, O'Fallon
- Springfield Clinic, Springfield
- Carle Cancer Center, Urbana
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06790693Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- University of Illinois Cancer Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04886531Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Northwestern University, Chicago
- Southern Illinois University-Simmons, Springfield
- Carle Foundation Cancer Institute-Urbana, Urbana
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06072612Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- y 54 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- y 83 más
ReclutandoFase 3
Edades de 18 a 60 · Mujeres · Actualizado el 2 sept 2026 · NCT05879926A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
ReclutandoSe aceptan voluntarios sanos
Edades de 25 en adelante · Mujeres · Actualizado el 1 sept 2026 · NCT03729115TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Chicago Medical Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06533826A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06764940BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- University of Illinois, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06441890ATEMPT 2.0: Adjuvant T-DM1 vs TH
- The University of Chicago Medical Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04893109De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.